Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease

PDE type 5 inhibitors (PDE5Is), such as sildenafil, tadalafil and vardenafil, are a class of drugs used to prolong the physiological effects of NO/cGMP signalling in tissues through the inhibition of cGMP degradation. Although these agents were originally developed for the treatment of hypertension...

Full description

Saved in:
Bibliographic Details
Published in:British journal of pharmacology Vol. 177; no. 24; pp. 5467 - 5488
Main Authors: Tzoumas, Nikolaos, Farrah, Tariq E., Dhaun, Neeraj, Webb, David J.
Format: Journal Article
Language:English
Published: England Blackwell Publishing Ltd 01.12.2020
John Wiley and Sons Inc
Subjects:
Angina
Cardiovascular diseases
Cerebral infarction
Cyclic GMP
Diabetes mellitus
Erectile dysfunction
Hypertension
Kidney diseases
Myocardial infarction
Review
Sildenafil
TARGETING THE NITRIC OXIDE (NO)‐cGMP PATHWAY: THERAPEUTIC OPPORTUNITIES IN THE 21ST CENTURY
ISSN:0007-1188, 1476-5381, 1476-5381
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract PDE type 5 inhibitors (PDE5Is), such as sildenafil, tadalafil and vardenafil, are a class of drugs used to prolong the physiological effects of NO/cGMP signalling in tissues through the inhibition of cGMP degradation. Although these agents were originally developed for the treatment of hypertension and angina, unanticipated side effects led to advances in the treatment of erectile dysfunction and, later, pulmonary arterial hypertension. In the last decade, accumulating evidence suggests that PDE5Is may confer a wider range of clinical benefits than was previously recognised. This has led to a broader interest in the cardiovascular therapeutic potential of PDE5Is, in conditions such as hypertension, myocardial infarction, stroke, peripheral arterial disease, chronic kidney disease and diabetes mellitus. Here, we review the pharmacological properties and established licensed uses of this class of drug, along with emerging therapeutic developments and possible future indications.
AbstractList PDE type 5 inhibitors (PDE5Is), such as sildenafil, tadalafil and vardenafil, are a class of drugs used to prolong the physiological effects of NO/cGMP signalling in tissues through the inhibition of cGMP degradation. Although these agents were originally developed for the treatment of hypertension and angina, unanticipated side effects led to advances in the treatment of erectile dysfunction and, later, pulmonary arterial hypertension. In the last decade, accumulating evidence suggests that PDE5Is may confer a wider range of clinical benefits than was previously recognised. This has led to a broader interest in the cardiovascular therapeutic potential of PDE5Is, in conditions such as hypertension, myocardial infarction, stroke, peripheral arterial disease, chronic kidney disease and diabetes mellitus. Here, we review the pharmacological properties and established licensed uses of this class of drug, along with emerging therapeutic developments and possible future indications.
PDE type 5 inhibitors (PDE5Is), such as sildenafil, tadalafil and vardenafil, are a class of drugs used to prolong the physiological effects of NO/cGMP signalling in tissues through the inhibition of cGMP degradation. Although these agents were originally developed for the treatment of hypertension and angina, unanticipated side effects led to advances in the treatment of erectile dysfunction and, later, pulmonary arterial hypertension. In the last decade, accumulating evidence suggests that PDE5Is may confer a wider range of clinical benefits than was previously recognised. This has led to a broader interest in the cardiovascular therapeutic potential of PDE5Is, in conditions such as hypertension, myocardial infarction, stroke, peripheral arterial disease, chronic kidney disease and diabetes mellitus. Here, we review the pharmacological properties and established licensed uses of this class of drug, along with emerging therapeutic developments and possible future indications.PDE type 5 inhibitors (PDE5Is), such as sildenafil, tadalafil and vardenafil, are a class of drugs used to prolong the physiological effects of NO/cGMP signalling in tissues through the inhibition of cGMP degradation. Although these agents were originally developed for the treatment of hypertension and angina, unanticipated side effects led to advances in the treatment of erectile dysfunction and, later, pulmonary arterial hypertension. In the last decade, accumulating evidence suggests that PDE5Is may confer a wider range of clinical benefits than was previously recognised. This has led to a broader interest in the cardiovascular therapeutic potential of PDE5Is, in conditions such as hypertension, myocardial infarction, stroke, peripheral arterial disease, chronic kidney disease and diabetes mellitus. Here, we review the pharmacological properties and established licensed uses of this class of drug, along with emerging therapeutic developments and possible future indications.
Author Farrah, Tariq E.
Dhaun, Neeraj
Webb, David J.
Tzoumas, Nikolaos
AuthorAffiliation 2 Institute of Genetic Medicine Newcastle University Newcastle Upon Tyne UK
1 British Heart Foundation/University Centre for Cardiovascular Science, Queen's Medical Research Institute University of Edinburgh Edinburgh UK
AuthorAffiliation_xml – name: 1 British Heart Foundation/University Centre for Cardiovascular Science, Queen's Medical Research Institute University of Edinburgh Edinburgh UK
– name: 2 Institute of Genetic Medicine Newcastle University Newcastle Upon Tyne UK
Author_xml – sequence: 1
  givenname: Nikolaos
  orcidid: 0000-0003-2081-6042
  surname: Tzoumas
  fullname: Tzoumas, Nikolaos
  organization: Newcastle University
– sequence: 2
  givenname: Tariq E.
  surname: Farrah
  fullname: Farrah, Tariq E.
  organization: University of Edinburgh
– sequence: 3
  givenname: Neeraj
  surname: Dhaun
  fullname: Dhaun, Neeraj
  organization: University of Edinburgh
– sequence: 4
  givenname: David J.
  surname: Webb
  fullname: Webb, David J.
  email: d.j.webb@ed.ac.uk
  organization: University of Edinburgh
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31721165$$D View this record in MEDLINE/PubMed
BookMark eNp9kUFrFTEQx4NU7Gv14BeQgJf2sG2ym31JLoLWpxUK9qA3ISTZyduUfZs1yba8b2_aV4sW2rnMwPzmz8z8D9DeGEZA6C0lJ7TEqZn6E8pkTV6gBWV8WbWNoHtoQQjhFaVC7KODlK4IKU3evkL7DeU1pct2gX6tUtZm8KmHDuuxw7CBuPbjGuceop5gzt7iOUHCweHLzyuctxPgFvux98bnEFMpsdWx8-FaJzsPOuLOJ9AJXqOXTg8J3tznQ_Tzy-rH2Xl18f3rt7OPF5VtiSSVEcyBaaRxkkhKGtktqZVOWCZFbRvhRMdtITRvLWfOci1cZ7QxQhhHGG0O0Yed7jSbDXQWxhz1oKboNzpuVdBe_d8Zfa_W4VpxTjglpAgc3QvE8HuGlNXGJwvDoEcIc1J1Q1ndtrVoCvr-EXoV5jiW81TNli1nTEhZqHf_bvSwyt_HF-B4B9gYUorgHhBK1K2pqpiq7kwt7Okj1vqssw-3x_jhuYkbP8D2aWn16fJ8N_EHWge0Cw
CitedBy_id crossref_primary_10_1038_s41390_020_0993_4
crossref_primary_10_3389_fendo_2024_1461642
crossref_primary_10_3390_jcm9051284
crossref_primary_10_1080_19440049_2021_1881623
crossref_primary_10_1139_cjpp_2020_0732
crossref_primary_10_2196_19199
crossref_primary_10_1183_16000617_0183_2023
crossref_primary_10_1016_j_preteyeres_2024_101248
crossref_primary_10_1038_s41419_024_06549_1
crossref_primary_10_1155_2021_7231658
crossref_primary_10_1002_pds_5721
crossref_primary_10_3390_ani14152218
crossref_primary_10_1080_14740338_2024_2355335
crossref_primary_10_1016_j_eururo_2025_05_004
crossref_primary_10_3390_ijms24010703
crossref_primary_10_1016_j_jsxm_2021_06_010
crossref_primary_10_1002_tcr_202300207
crossref_primary_10_1016_j_biopha_2022_112894
crossref_primary_10_1155_2022_4716572
crossref_primary_10_1093_ehjcvp_pvaf015
crossref_primary_10_1007_s12274_022_5310_6
crossref_primary_10_1016_j_ajoc_2021_101228
crossref_primary_10_1111_jth_15844
crossref_primary_10_2196_19583
crossref_primary_10_1038_s41569_021_00593_6
crossref_primary_10_1016_j_niox_2023_12_003
crossref_primary_10_1016_j_heliyon_2024_e36317
crossref_primary_10_1007_s43440_025_00694_w
crossref_primary_10_1007_s00210_024_03556_z
crossref_primary_10_3390_ijms22126448
crossref_primary_10_3390_cells14090663
crossref_primary_10_1111_cbdd_14140
crossref_primary_10_2217_fca_2020_0201
crossref_primary_10_17826_cumj_1457346
crossref_primary_10_1515_dmdi_2023_0011
crossref_primary_10_1111_apha_13641
crossref_primary_10_31083_j_fbl2807155
crossref_primary_10_1016_j_cellsig_2022_110251
crossref_primary_10_1177_22840265221094405
crossref_primary_10_1186_s12610_024_00245_y
crossref_primary_10_3390_ijms21218244
crossref_primary_10_1039_D3SC03849A
crossref_primary_10_3389_fcvm_2023_1079142
crossref_primary_10_1007_s10557_021_07275_y
crossref_primary_10_1016_j_compbiolchem_2024_108239
crossref_primary_10_2147_CPAA_S289323
crossref_primary_10_1007_s00210_023_02787_w
crossref_primary_10_3389_fphar_2022_1057083
crossref_primary_10_1016_j_jaccao_2024_04_006
crossref_primary_10_1002_chem_202003830
crossref_primary_10_26508_lsa_202403094
crossref_primary_10_1016_S1875_5364_24_60616_3
crossref_primary_10_52711_2231_5691_2023_00012
crossref_primary_10_3390_ijms25179441
crossref_primary_10_3390_ph16040503
crossref_primary_10_1093_cvr_cvac187
crossref_primary_10_3390_cells14020120
crossref_primary_10_1007_s11030_024_11016_2
crossref_primary_10_1016_j_neuint_2024_105883
crossref_primary_10_1155_2023_5852315
crossref_primary_10_3390_ijms26073073
crossref_primary_10_1111_aogs_14251
crossref_primary_10_1002_jmv_27683
crossref_primary_10_1007_s00580_024_03611_4
crossref_primary_10_1038_s41419_021_03922_2
crossref_primary_10_3390_cimb46080521
crossref_primary_10_1016_j_fitote_2025_106753
crossref_primary_10_1155_2021_3554718
crossref_primary_10_3390_ijms23010262
Cites_doi 10.1093/rheumatology/ket417
10.1097/WNO.0000000000000299
10.1046/j.1365-2125.2000.00245.x
10.1161/CIRCULATIONAHA.112.000056
10.1161/CIRCULATIONAHA.110.983866
10.1074/jbc.M404706200
10.1016/j.neuropharm.2012.06.052
10.1093/rheumatology/keq291
10.1136/annrheumdis-2014-207001
10.1111/bph.14533
10.1056/NEJMoa050010
10.1161/ATVBAHA.108.169722
10.7326/M18-0517
10.1161/CIRCULATIONAHA.107.742510
10.1016/j.amjhyper.2004.07.004
10.1016/S0002-9149(99)00044-2
10.1038/nrd2030
10.1016/j.freeradbiomed.2013.01.031
10.1111/j.1743-6109.2007.00723.x
10.1007/s00228-013-1611-8
10.1053/j.ajkd.2014.09.023
10.1016/S0002-9149(99)00043-0
10.1111/bph.14532
10.1002/14651858.CD012621.pub2
10.1007/s00395-012-0249-5
10.1517/13543784.2013.793672
10.1111/bph.14752
10.1056/NEJM199805143382001
10.1016/j.vph.2019.05.003
10.1152/ajprenal.00473.2015
10.1016/j.urology.2017.02.044
10.1111/j.1365-2125.2009.03375.x
10.1161/JAHA.114.001001
10.1111/bph.14540
10.2337/db06-0883
10.1002/ejhf.662
10.2337/db11-0255
10.1016/j.yjmcc.2007.10.006
10.1111/jnc.13454
10.1186/1479-5876-12-35
10.1038/sj.bjp.0706495
10.1093/eurheartj/ehm010
10.2337/dc09-1727
10.1111/j.1743-6109.2012.02822.x
10.1016/j.jstrokecerebrovasdis.2015.11.026
10.1038/s41569-019-0176-3
10.1111/bph.14205
10.2174/138161209789206971
10.1371/journal.pone.0045243
10.1016/j.bbrc.2005.06.183
10.1093/ndt/gfs391
10.1016/j.jsxm.2016.01.016
10.4065/84.2.139
10.1371/journal.pone.0119623
10.1016/j.jacc.2007.10.069
10.1161/01.CIR.101.6.676
10.1038/sj.ijir.3901522
10.1056/NEJM200006153422407
10.1210/jc.2015-3415
10.1002/uog.19186
10.1001/archinte.166.2.231
10.1136/annrheumdis-2012-202836
10.1016/S0002-9149(03)00075-4
10.1124/jpet.110.170191
10.1016/S0140-6736(16)31134-5
10.1056/NEJMoa041031
10.1056/NEJMoa1811744
10.1136/heartjnl-2017-312865
10.1159/000334952
10.1152/ajpheart.00129.2010
10.1161/HYPERTENSIONAHA.109.147686
10.1016/j.jacc.2004.02.031
10.1097/00004872-200502000-00001
10.1111/j.1743-6109.2009.01375.x
10.1007/s00228-013-1571-z
10.1183/13993003.01913-2018
10.1177/0271678X17747177
10.1002/j.1939-4640.2004.tb02833.x
10.1016/j.amjmed.2012.08.015
10.1161/HYPERTENSIONAHA.109.132225
10.1001/archinternmed.2012.2271
10.2165/00003495-200565120-00003
10.1111/bph.12959
10.1136/heartjnl-2015-309223
10.1152/ajpheart.00324.2002
10.1001/jama.2013.2024
10.1016/j.jaad.2017.08.018
10.1056/NEJMoa1213917
10.1016/0165-6147(90)90066-H
10.1038/sj.bjp.0707409
10.1074/jbc.M210618200
10.1016/0006-291X(90)92168-Y
10.1161/01.CIR.0000160359.49478.C2
10.1111/jsm.12726
10.1016/j.diabres.2007.02.006
10.1016/j.urology.2017.02.032
10.1152/ajprenal.00212.2013
10.1016/S2213-2600(15)00542-1
10.1016/S2352-4642(19)30020-3
10.1097/FJC.0b013e318157fd5b
10.1097/01.CCM.0000269371.70738.30
10.1161/CIRCULATIONAHA.111.063412
10.1097/00000542-199802000-00020
10.1517/13543784.2010.518955
10.1016/0960-894X(96)00323-X
10.1111/j.1742-1241.2009.02254.x
10.1007/s11010-013-1625-7
10.1164/ajrccm.158.5.9710117
10.1111/j.1743-6109.2008.01079.x
10.1111/bph.14167
10.1161/HYPERTENSIONAHA.113.01774
10.1111/j.1743-6109.2008.00945.x
10.1016/j.bbrc.2010.05.064
10.1161/ATVBAHA.109.199893
10.1161/CIRCRESAHA.117.308903
10.1161/CIRCHEARTFAILURE.115.003011
10.1007/s00125-010-1819-4
10.1161/ATVBAHA.107.147421
10.1046/j.0306-5251.2001.00029.x
10.1161/CIRCULATIONAHA.116.022194
10.1093/nar/gkx1121
10.1203/00006450-199802000-00002
10.1530/EJE-15-1100
10.1016/j.amjcard.2004.02.034
10.1378/chest.10-0969
10.3389/fphys.2016.00015
10.1016/j.yjmcc.2006.10.015
10.1002/14651858.CD011205.pub2
10.1152/ajpheart.ajpheart.91438.2007
10.1038/sj.jhh.1001244
10.1371/journal.pone.0014542
10.1152/ajpheart.00215.2014
10.1186/1475-2840-11-67
10.1161/01.HYP.0000239816.13007.c9
10.1056/NEJMoa1413687
10.1111/bph.13868
10.1161/CIRCULATIONAHA.108.822072
10.1016/S0895-7061(00)01177-8
10.1007/s12272-009-1801-1
10.1016/S0735-1097(98)00656-1
10.1007/s11906-016-0646-5
10.18388/abp.2011_2271
10.1161/ATVBAHA.109.201327
10.1681/ASN.2015050473
10.1016/j.yjmcc.2011.02.013
10.2165/00003495-200868020-00006
ContentType Journal Article
Copyright 2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society
2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
2019. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society
– notice: 2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
– notice: 2019. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
AAYXX
CITATION
NPM
7QP
7TK
K9.
NAPCQ
7X8
5PM
DOI 10.1111/bph.14920
DatabaseName Wiley Online Library Open Access
CrossRef
PubMed
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
MEDLINE - Academic
DatabaseTitleList CrossRef
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic


PubMed
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Tzoumas et al
EISSN 1476-5381
EndPage 5488
ExternalDocumentID PMC7707100
31721165
10_1111_bph_14920
BPH14920
Genre reviewArticle
Research Support, Non-U.S. Gov't
Journal Article
Review
GrantInformation_xml – fundername: BHF Intermediate Clinical Research Fellowship
  funderid: FS/13/30/29994
– fundername: MRC Clinical Research Training Fellowship
  funderid: MR/R017840/1
– fundername: British Heart Foundation (BHF) Centre of Research Excellence Award
  funderid: RE/08/001/23904
– fundername: British Heart Foundation (BHF) Centre of Research Excellence Award
  grantid: RE/08/001/23904
– fundername: MRC Clinical Research Training Fellowship
  grantid: MR/R017840/1
– fundername: BHF Intermediate Clinical Research Fellowship
  grantid: FS/13/30/29994
GroupedDBID ---
.3N
.55
.GJ
05W
0R~
1OC
23N
24P
2WC
31~
33P
36B
3O-
3SF
3V.
4.4
52U
52V
53G
5GY
6J9
7RV
7X7
8-0
8-1
88E
8AO
8FE
8FH
8FI
8FJ
8R4
8R5
8UM
A00
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCUV
ABDBF
ABPVW
ABQWH
ABUWG
ABXGK
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACUHS
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFKRA
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHMBA
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
AOIJS
ATUGU
AZBYB
AZVAB
B0M
BAFTC
BAWUL
BBNVY
BENPR
BFHJK
BHBCM
BHPHI
BKEYQ
BMXJE
BPHCQ
BRXPI
BVXVI
C45
CAG
CCPQU
COF
CS3
DCZOG
DIK
DRFUL
DRMAN
DRSTM
DU5
E3Z
EAD
EAP
EAS
EBC
EBD
EBS
ECV
EJD
EMB
EMK
EMOBN
ENC
ESX
EX3
F5P
FUBAC
FYUFA
G-S
GODZA
GX1
H.X
HCIFZ
HGLYW
HMCUK
HYE
HZ~
J5H
KBYEO
LATKE
LEEKS
LH4
LITHE
LK8
LOXES
LSO
LUTES
LW6
LYRES
M1P
M7P
MEWTI
MK0
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
MY~
N9A
NAPCQ
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P4E
PQQKQ
PROAC
PSQYO
Q.N
Q2X
QB0
RIG
ROL
RPM
RWI
SJN
SUPJJ
SV3
TEORI
TR2
TUS
UKHRP
UPT
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WVDHM
WXSBR
X7M
XV2
Y6R
YHG
ZGI
ZXP
ZZTAW
~8M
~S-
1OB
AAFWJ
AAMMB
AAYXX
AEFGJ
AEYWJ
AFFHD
AGHNM
AGXDD
AGYGG
AIDQK
AIDYY
CITATION
O8X
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
NPM
7QP
7TK
K9.
7X8
5PM
ID FETCH-LOGICAL-c5090-b84feb39bf9091039d61c9f8c4982c38f8d7cfeba75c74fc7a8fdbabb88bf0413
IEDL.DBID 24P
ISICitedReferencesCount 81
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000510759200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0007-1188
1476-5381
IngestDate Tue Nov 04 02:00:54 EST 2025
Fri Sep 05 07:33:36 EDT 2025
Mon Oct 06 18:37:37 EDT 2025
Mon Jul 21 05:24:53 EDT 2025
Sat Nov 29 04:20:54 EST 2025
Tue Nov 18 22:46:20 EST 2025
Wed Jan 22 16:31:19 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 24
Language English
License Attribution
2019 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5090-b84feb39bf9091039d61c9f8c4982c38f8d7cfeba75c74fc7a8fdbabb88bf0413
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0003-2081-6042
OpenAccessLink https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbph.14920
PMID 31721165
PQID 2465744899
PQPubID 42104
PageCount 22
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7707100
proquest_miscellaneous_2314255283
proquest_journals_2465744899
pubmed_primary_31721165
crossref_primary_10_1111_bph_14920
crossref_citationtrail_10_1111_bph_14920
wiley_primary_10_1111_bph_14920_BPH14920
PublicationCentury 2000
PublicationDate December 2020
PublicationDateYYYYMMDD 2020-12-01
PublicationDate_xml – month: 12
  year: 2020
  text: December 2020
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
– name: Hoboken
PublicationTitle British journal of pharmacology
PublicationTitleAlternate Br J Pharmacol
PublicationYear 2020
Publisher Blackwell Publishing Ltd
John Wiley and Sons Inc
Publisher_xml – name: Blackwell Publishing Ltd
– name: John Wiley and Sons Inc
References 2013; 3
2009; 84
2013; 69
2010; 19
2013; 127
2005; 334
2004; 25
2013; 369
2011; 60
2013; 126
2013; 64
2018; 169
2016; 388
2019; 16
2005; 65
1998; 158
2011; 58
2012; 125
2009; 119
2003; 278
2007; 78
2012; 11
2016; 36
1998; 88
2018; 46
2018; 175
2011; 124
2013; 53
2015; 373
2008; 28
1990; 170
2016; 310
2013; 60
2008; 117
2012; 28
2014; 12
2018; 38
2010; 30
2006; 166
2009; 15
2004; 43
2009; 67
2010; 33
2007; 19
2019; 3
2005; 111
2005; 353
2018; 104
2016; 18
2008; 51
2012; 35
2011; 6
2012; 107
2016; 13
2019; 118‐119
2016; 4
2014; 306
2016; 7
2010; 49
2014; 307
2010; 334
2013; 72
2007; 152
2010; 299
2015; 65
2006; 48
1999; 33
2008; 44
2000; 342
2000; 101
2011; 140
2016; 27
2016; 25
2016; 9
2016; 174
2019; 176
2010; 56
2010; 53
1990; 11
2014; 70
2019; 53
2013; 22
2002; 53
2015; 100
2016; 102
2000; 50
2016; 75
2008; 5
1999; 83
2014; 63
1998; 43
2007; 35
2005; 23
2012; 172
2007; 28
2010; 64
2015; 172
2014; 3
2003; 92
2009; 53
2017; 35
2010; 396
2008; 68
2001; 15
2017; 121
2018; 78
2001; 14
1996; 8
1996; 6
2007; 27
2015; 12
2013; 309
2015; 10
1998; 338
2006; 5
2007; 50
2017; 174
2019; 380
2007; 56
2005; 280
2004; 351
2009; 32
2004; 93
2002; 283
2004; 17
2013; 379
2011; 50
2019
2016; 133
2018; 52
2017; 19
2016
2009; 6
2014
2016; 136
2007; 42
2012; 7
2017; 105
2008; 294
2006; 147
2012; 9
e_1_2_12_130_1
e_1_2_12_2_1
e_1_2_12_17_1
e_1_2_12_111_1
e_1_2_12_138_1
e_1_2_12_115_1
e_1_2_12_134_1
e_1_2_12_108_1
e_1_2_12_20_1
e_1_2_12_66_1
e_1_2_12_43_1
e_1_2_12_85_1
e_1_2_12_24_1
e_1_2_12_47_1
e_1_2_12_89_1
e_1_2_12_62_1
e_1_2_12_81_1
e_1_2_12_100_1
e_1_2_12_123_1
e_1_2_12_146_1
e_1_2_12_28_1
e_1_2_12_104_1
e_1_2_12_127_1
e_1_2_12_142_1
e_1_2_12_31_1
e_1_2_12_77_1
e_1_2_12_54_1
e_1_2_12_96_1
e_1_2_12_139_1
e_1_2_12_35_1
e_1_2_12_58_1
e_1_2_12_12_1
e_1_2_12_73_1
e_1_2_12_50_1
e_1_2_12_92_1
e_1_2_12_3_1
e_1_2_12_152_1
e_1_2_12_18_1
Boolell M. (e_1_2_12_11_1) 1996; 8
e_1_2_12_110_1
e_1_2_12_137_1
e_1_2_12_114_1
e_1_2_12_133_1
e_1_2_12_21_1
e_1_2_12_44_1
e_1_2_12_63_1
e_1_2_12_86_1
e_1_2_12_107_1
e_1_2_12_25_1
e_1_2_12_48_1
e_1_2_12_67_1
Levin A. (e_1_2_12_78_1) 2013; 3
e_1_2_12_40_1
e_1_2_12_82_1
e_1_2_12_141_1
e_1_2_12_122_1
e_1_2_12_29_1
e_1_2_12_149_1
e_1_2_12_126_1
e_1_2_12_103_1
e_1_2_12_145_1
e_1_2_12_119_1
e_1_2_12_32_1
e_1_2_12_55_1
e_1_2_12_74_1
e_1_2_12_97_1
e_1_2_12_36_1
e_1_2_12_59_1
e_1_2_12_13_1
e_1_2_12_7_1
e_1_2_12_51_1
e_1_2_12_70_1
e_1_2_12_93_1
e_1_2_12_4_1
e_1_2_12_151_1
e_1_2_12_19_1
e_1_2_12_38_1
e_1_2_12_136_1
e_1_2_12_132_1
e_1_2_12_113_1
e_1_2_12_41_1
e_1_2_12_87_1
e_1_2_12_106_1
e_1_2_12_129_1
Andrigueti F. (e_1_2_12_6_1) 2017; 35
e_1_2_12_22_1
e_1_2_12_64_1
e_1_2_12_45_1
e_1_2_12_26_1
e_1_2_12_68_1
e_1_2_12_83_1
e_1_2_12_60_1
e_1_2_12_140_1
e_1_2_12_49_1
e_1_2_12_121_1
e_1_2_12_148_1
e_1_2_12_102_1
e_1_2_12_125_1
e_1_2_12_144_1
e_1_2_12_52_1
e_1_2_12_98_1
e_1_2_12_118_1
e_1_2_12_33_1
e_1_2_12_75_1
e_1_2_12_56_1
e_1_2_12_37_1
e_1_2_12_79_1
e_1_2_12_14_1
e_1_2_12_90_1
e_1_2_12_8_1
e_1_2_12_10_1
e_1_2_12_94_1
e_1_2_12_71_1
e_1_2_12_150_1
e_1_2_12_5_1
e_1_2_12_16_1
e_1_2_12_112_1
e_1_2_12_135_1
e_1_2_12_39_1
e_1_2_12_116_1
e_1_2_12_131_1
e_1_2_12_42_1
e_1_2_12_65_1
e_1_2_12_88_1
e_1_2_12_109_1
e_1_2_12_128_1
e_1_2_12_23_1
e_1_2_12_46_1
e_1_2_12_69_1
e_1_2_12_80_1
e_1_2_12_61_1
e_1_2_12_84_1
e_1_2_12_27_1
e_1_2_12_101_1
e_1_2_12_147_1
e_1_2_12_120_1
e_1_2_12_105_1
e_1_2_12_143_1
e_1_2_12_124_1
e_1_2_12_30_1
e_1_2_12_53_1
e_1_2_12_76_1
e_1_2_12_99_1
e_1_2_12_117_1
e_1_2_12_34_1
e_1_2_12_57_1
e_1_2_12_15_1
e_1_2_12_91_1
e_1_2_12_72_1
e_1_2_12_95_1
e_1_2_12_9_1
References_xml – volume: 176
  start-page: 197
  year: 2019
  end-page: 211
  article-title: NO as a multimodal transmitter in the brain: Discovery and current status
  publication-title: British Journal of Pharmacology
– volume: 65
  start-page: 1621
  year: 2005
  end-page: 1650
  article-title: A comparative review of the options for treatment of erectile dysfunction
  publication-title: Drugs
– volume: 6
  start-page: 1819
  year: 1996
  end-page: 1824
  article-title: Sildenafil (VIAGRA™), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction
  publication-title: Bioorganic & Medicinal Chemistry Letters
– volume: 176
  start-page: 131
  year: 2019
  end-page: 134
  article-title: Nitric oxide is not just blowing in the wind
  publication-title: British Journal of Pharmacology
– volume: 27
  start-page: 3459
  year: 2016
  end-page: 3468
  article-title: Phosphodiesterase type 5 inhibition reduces albuminuria in subjects with overt diabetic nephropathy
  publication-title: J Am Soc Nephrol
– volume: 280
  start-page: 12944
  year: 2005
  end-page: 12955
  article-title: Phosphodiesterase‐5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling
  publication-title: The Journal of Biological Chemistry
– volume: 140
  start-page: 1274
  year: 2011
  end-page: 1283
  article-title: Long‐term treatment with sildenafil citrate in pulmonary arterial hypertension: The SUPER‐2 study
  publication-title: Chest
– volume: 4
  start-page: 323
  year: 2016
  end-page: 336
  article-title: Treatment of pulmonary hypertension
  publication-title: The Lancet Respiratory Medicine
– volume: 172
  start-page: 1996
  year: 2015
  end-page: 2009
  article-title: The cGMP/PKG pathway as a common mediator of cardioprotection: Translatability and mechanism
  publication-title: British Journal of Pharmacology
– volume: 299
  start-page: H827
  year: 2010
  end-page: H836
  article-title: Phospholemman Ser69 phosphorylation contributes to sildenafil‐induced cardioprotection against reperfusion injury
  publication-title: American Journal of Physiology. Heart and Circulatory Physiology
– volume: 380
  start-page: 2295
  year: 2019
  end-page: 2306
  article-title: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
  publication-title: The New England Journal of Medicine
– volume: 294
  start-page: H1398
  year: 2008
  end-page: H1406
  article-title: Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice
  publication-title: American Journal of Physiology. Heart and Circulatory Physiology
– volume: 53
  start-page: 658
  year: 2013
  end-page: 664
  article-title: Head‐to‐head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud's phenomenon: A double‐blind, randomized, cross‐over study
  publication-title: Rheumatology
– volume: 176
  start-page: 1038
  year: 2019
  end-page: 1050
  article-title: Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system
  publication-title: British Journal of Pharmacology
– volume: 118‐119
  start-page: 106563
  year: 2019
  article-title: Effects of sildenafil on maximum walking time in patients with arterial claudication: The ARTERIOFIL study
  publication-title: Vascular Pharmacology
– volume: 351
  start-page: 1296
  year: 2004
  end-page: 1305
  article-title: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
  publication-title: The New England Journal of Medicine
– volume: 310
  start-page: F748
  year: 2016
  end-page: F754
  article-title: Angiotensin II‐mediated hypertension impairs nitric oxide‐induced NKCC2 inhibition in thick ascending limbs
  publication-title: American Journal of Physiology. Renal Physiology
– volume: 28
  start-page: 1751
  year: 2012
  end-page: 1761
  article-title: Selective phosphodiesterase‐5 (PDE‐5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3′, 5′ guanosine monophosphate (cGMP) level in podocytes
  publication-title: Nephrology, Dialysis, Transplantation
– volume: 35
  start-page: 273
  year: 2012
  end-page: 280
  article-title: Sildenafil treatment prevents glomerular hypertension and hyperfiltration in rats with renal ablation
  publication-title: Kidney & Blood Pressure Research
– volume: 78
  start-page: 136
  year: 2007
  end-page: 140
  article-title: Sildenafil citrate diminishes microalbuminuria and the percentage of A1c in male patients with type 2 diabetes
  publication-title: Diabetes Research and Clinical Practice
– year: 2014
– volume: 43
  start-page: 163
  year: 1998
  end-page: 168
  article-title: Cyclic‐GMP‐binding, cyclic‐GMP‐specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development
  publication-title: Pediatric Research
– volume: 111
  start-page: 1601
  year: 2005
  end-page: 1610
  article-title: Phosphodiesterase‐5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity
  publication-title: Circulation
– volume: 166
  start-page: 231
  year: 2006
  end-page: 233
  article-title: Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease
  publication-title: Archives of Internal Medicine
– volume: 68
  start-page: 231
  year: 2008
  end-page: 250
  article-title: Looking to the future for erectile dysfunction therapies
  publication-title: Drugs
– volume: 334
  start-page: 1023
  year: 2010
  end-page: 1030
  article-title: Long‐acting phosphodiesterase‐5 inhibitor tadalafil attenuates doxorubicin‐induced cardiomyopathy without interfering with chemotherapeutic effect
  publication-title: The Journal of Pharmacology and Experimental Therapeutics
– volume: 17
  start-page: 1135
  year: 2004
  end-page: 1142
  article-title: Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: A randomized controlled trial
  publication-title: American Journal of Hypertension
– volume: 19
  start-page: 116
  year: 2017
  end-page: 125
  article-title: Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health‐related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension
  publication-title: European Journal of Heart Failure
– volume: 14
  start-page: 70
  year: 2001
  end-page: 73
  article-title: Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy
  publication-title: American Journal of Hypertension
– volume: 60
  start-page: 2792
  year: 2011
  end-page: 2801
  article-title: Endothelial NO/cGMP/VASP signaling attenuates Kupffer cell activation and hepatic insulin resistance induced by high‐fat feeding
  publication-title: Diabetes
– volume: 25
  start-page: 642
  year: 2016
  end-page: 649
  article-title: Phosphodiesterase‐5 inhibitor PF‐03049423 effect on stroke recovery: A double‐blind, placebo‐controlled randomized clinical trial
  publication-title: Journal of Stroke and Cerebrovascular Diseases
– volume: 13
  start-page: 465
  year: 2016
  end-page: 488
  article-title: Pharmacotherapy for erectile dysfunction: recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015)
  publication-title: The Journal of Sexual Medicine
– volume: 33
  start-page: 273
  year: 1999
  end-page: 282
  article-title: Use of sildenafil (Viagra) in patients with cardiovascular disease
  publication-title: Journal of the American College of Cardiology
– volume: 65
  start-page: 403
  year: 2015
  end-page: 411
  article-title: The future burden of CKD in the United States: A simulation model for the CDC CKD initiative
  publication-title: American Journal of Kidney Diseases
– volume: 53
  start-page: 2205
  year: 2010
  end-page: 2208
  article-title: Tadalafil increases muscle capillary recruitment and forearm glucose uptake in women with type 2 diabetes
  publication-title: Diabetologia
– volume: 30
  start-page: 758
  year: 2010
  end-page: 765
  article-title: Reduced NO‐cGMP signaling contributes to vascular inflammation and insulin resistance induced by high‐fat feeding
  publication-title: Arteriosclerosis, Thrombosis, and Vascular Biology
– volume: 33
  start-page: 1859
  year: 2010
  end-page: 1864
  article-title: The effect of oral antidiabetic agents on A1C levels
  publication-title: Diabetes Care
– volume: 28
  start-page: 1982
  year: 2008
  end-page: 1988
  article-title: Vascular inflammation, insulin resistance, and reduced nitric oxide production precede the onset of peripheral insulin resistance
  publication-title: Arteriosclerosis, Thrombosis, and Vascular Biology
– volume: 53
  start-page: 1091
  year: 2009
  end-page: 1097
  article-title: Blood pressure lowering effects of a new long‐acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension
  publication-title: Hypertension
– volume: 147
  start-page: S252
  year: 2006
  end-page: S257
  article-title: Phosphodiesterase inhibitors
  publication-title: British Journal of Pharmacology
– volume: 49
  start-page: 2420
  year: 2010
  end-page: 2428
  article-title: Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: A double‐blind randomized cross‐over trial
  publication-title: Rheumatology
– year: 2019
– volume: 83
  start-page: 13
  year: 1999
  end-page: 20
  article-title: Effects of sildenafil citrate on human hemodynamics
  publication-title: The American Journal of Cardiology
– volume: 27
  start-page: 1947
  year: 2007
  end-page: 1954
  article-title: Sildenafil promotes ischemia‐induced angiogenesis through a PKG‐dependent pathway
  publication-title: Arteriosclerosis, Thrombosis, and Vascular Biology
– volume: 15
  start-page: 3464
  year: 2009
  end-page: 3475
  article-title: PDE5 inhibitors: in vitro and in vivo pharmacological profile
  publication-title: Current Pharmaceutical Design
– volume: 83
  start-page: 21
  year: 1999
  end-page: 28
  article-title: Sildenafil citrate and blood‐pressure–lowering drugs: Results of drug interaction studies with an organic nitrate and a calcium antagonist
  publication-title: The American Journal of Cardiology
– volume: 22
  start-page: 843
  year: 2013
  end-page: 851
  article-title: Targeting nitric oxide in the subacute restorative treatment of ischemic stroke
  publication-title: Expert Opinion on Investigational Drugs
– volume: 334
  start-page: 930
  year: 2005
  end-page: 938
  article-title: High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitors
  publication-title: Biochemical and Biophysical Research Communications
– volume: 5
  start-page: 946
  year: 2008
  end-page: 953
  article-title: The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction
  publication-title: The Journal of Sexual Medicine
– volume: 52
  start-page: 295
  year: 2018
  end-page: 296
  article-title: Clinicians should stop prescribing sildenafil for fetal growth restriction (FGR): Comment from the STRIDER Consortium
  publication-title: Ultrasound in Obstetrics & Gynecology
– volume: 105
  start-page: 76
  year: 2017
  end-page: 84
  article-title: Prospective case‐crossover study investigating the possible association between nonarteritic anterior ischemic optic neuropathy and phosphodiesterase type 5 inhibitor exposure
  publication-title: Urology
– volume: 51
  start-page: 2040
  year: 2008
  end-page: 2044
  article-title: Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease
  publication-title: Journal of the American College of Cardiology
– volume: 38
  start-page: 189
  year: 2018
  end-page: 203
  article-title: The effect of phosphodiesterase‐5 inhibitors on cerebral blood flow in humans: A systematic review
  publication-title: Journal of Cerebral Blood Flow & Metabolism
– volume: 69
  start-page: 2027
  year: 2013
  end-page: 2036
  article-title: Acute cardiac and hemodynamic effects of sildenafil on resistant hypertension
  publication-title: European Journal of Clinical Pharmacology
– volume: 373
  start-page: 834
  year: 2015
  end-page: 844
  article-title: Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension
  publication-title: The New England Journal of Medicine
– volume: 5
  start-page: 2672
  year: 2008
  end-page: 2680
  article-title: Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction
  publication-title: The Journal of Sexual Medicine
– volume: 50
  start-page: 99
  year: 2000
  end-page: 107
  article-title: Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir
  publication-title: British Journal of Clinical Pharmacology
– volume: 309
  start-page: 1268
  year: 2013
  end-page: 1277
  article-title: Effect of phosphodiesterase‐5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial
  publication-title: JAMA
– volume: 63
  start-page: 5
  year: 2014
  end-page: 11
  article-title: Potential therapeutic role of phosphodiesterase type 5 inhibition in hypertension and chronic kidney disease
  publication-title: Hypertension
– volume: 48
  start-page: 622
  year: 2006
  end-page: 627
  article-title: Effect of regular phosphodiesterase type 5 inhibition in hypertension
  publication-title: Hypertension
– volume: 306
  start-page: F1442
  year: 2014
  end-page: F1450
  article-title: Phosphodiesterase 5 inhibition ameliorates angiontensin II‐induced podocyte dysmotility via the protein kinase G‐mediated downregulation of TRPC6 activity
  publication-title: American Journal of Physiology. Renal Physiology
– volume: 16
  start-page: 491
  year: 2019
  end-page: 502
  article-title: Endothelins in cardiovascular biology and therapeutics
  publication-title: Nature Reviews. Cardiology
– volume: 42
  start-page: 453
  year: 2007
  end-page: 458
  article-title: Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K ATP channels when administered at reperfusion following ischemia in rabbits
  publication-title: Journal of Molecular and Cellular Cardiology
– volume: 105
  start-page: 54
  year: 2017
  end-page: 61
  article-title: The effect of oral phosphodiesterase‐5 inhibitors on sperm parameters: A meta‐analysis and systematic review
  publication-title: Urology
– volume: 28
  start-page: 806
  year: 2007
  end-page: 813
  article-title: Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non‐ST‐elevation acute coronary syndromes: Analyses from OPUS‐TIMI 16 and TACTICS‐TIMI 18
  publication-title: European Heart Journal
– volume: 32
  start-page: 1103
  year: 2009
  end-page: 1108
  article-title: Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases
  publication-title: Archives of Pharmacal Research
– volume: 67
  start-page: 403
  year: 2009
  end-page: 412
  article-title: Time‐dependent interactions of the hypotensive effects of sildenafil citrate and sublingual glyceryl trinitrate
  publication-title: British Journal of Clinical Pharmacology
– volume: 19
  start-page: 253
  year: 2007
  end-page: 264
  article-title: The role of pharmacokinetics and pharmacodynamics in phosphodiesterase‐5 inhibitor therapy
  publication-title: International Journal of Impotence Research
– volume: 175
  start-page: 2554
  year: 2018
  end-page: 2565
  article-title: PDE5 inhibitors—Pharmacology and clinical applications 20 years after sildenafil discovery
  publication-title: British Journal of Pharmacology
– volume: 101
  start-page: 676
  year: 2000
  end-page: 681
  article-title: Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo
  publication-title: Circulation
– volume: 8
  start-page: 47
  year: 1996
  end-page: 52
  article-title: Sildenafil: An orally active type 5 cyclic GMP‐specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction
  publication-title: International Journal of Impotence Research
– volume: 158
  start-page: 1388
  year: 1998
  end-page: 1395
  article-title: Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension
  publication-title: American Journal of Respiratory and Critical Care Medicine
– volume: 25
  start-page: 625
  year: 2004
  end-page: 629
  article-title: Cardiovascular parameter changes in patients with erectile dysfunction using PDE‐5 inhibitors: A study with sildenafil and vardenafil
  publication-title: Journal of Andrology
– volume: 6
  start-page: 2547
  year: 2009
  end-page: 2560
  article-title: The ENDOTRIAL study: A spontaneous, open‐label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction
  publication-title: The Journal of Sexual Medicine
– volume: 125
  start-page: 2323
  year: 2012
  end-page: 2333
  article-title: Chronic inhibition of cyclic GMP phosphodiesterase 5A improves diabetic cardiomyopathy: A randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging
  publication-title: Circulation
– volume: 126
  start-page: 192
  year: 2013
  end-page: 199
  article-title: Phosphodiesterase type 5 inhibitors improve endothelial function and may benefit cardiovascular conditions
  publication-title: The American Journal of Medicine
– volume: 92
  start-page: 47
  year: 2003
  end-page: 57
  article-title: Cardiovascular effects of tadalafil in patients on common antihypertensive therapies
  publication-title: The American Journal of Cardiology
– volume: 12
  start-page: 139
  year: 2015
  end-page: 151
  article-title: Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors
  publication-title: The Journal of Sexual Medicine
– volume: 3
  start-page: 1
  year: 2013
  end-page: 150
  article-title: Kidney disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease
  publication-title: Kidney International. Supplement
– volume: 7
  start-page: 15
  year: 2016
  article-title: Inhibition of PDE5 restores depressed baroreflex sensitivity in renovascular hypertensive rats
  publication-title: Frontiers in Physiology
– volume: 174
  start-page: 513
  year: 2016
– volume: 121
  start-page: 677
  year: 2017
  end-page: 694
  article-title: Reducing the global burden of cardiovascular disease, part 1: The epidemiology and risk factors
  publication-title: Circulation Research
– volume: 64
  start-page: 240
  year: 2010
  end-page: 255
  article-title: Safety of sildenafil citrate: Review of 67 double‐blind placebo‐controlled trials and the postmarketing safety database
  publication-title: International Journal of Clinical Practice. Supplement
– volume: 100
  start-page: 4533
  year: 2015
  end-page: 4540
  article-title: Treatment with sildenafil improves insulin sensitivity in prediabetes: A randomized, controlled trial
  publication-title: The Journal of Clinical Endocrinology and Metabolism
– volume: 7
  year: 2012
  article-title: Anti‐inflammatory and cardioprotective effects of tadalafil in diabetic mice
  publication-title: PLoS ONE
– volume: 133
  start-page: 2459
  year: 2016
  end-page: 2502
  article-title: Clinical update: Cardiovascular disease in diabetes mellitus
  publication-title: Circulation
– volume: 64
  start-page: 114
  year: 2013
  end-page: 123
  article-title: Tadalafil crosses the blood–brain barrier and reverses cognitive dysfunction in a mouse model of AD
  publication-title: Neuropharmacology
– volume: 169
  start-page: 694
  year: 2018
  end-page: 703
  article-title: On‐demand sildenafil as a treatment for Raynaud phenomenon: A series of n‐of‐1 trials
  publication-title: Annals of Internal Medicine
– volume: 30
  start-page: 1315
  year: 2010
  end-page: 1324
  article-title: A phosphodiesterase‐5 inhibitor vardenafil enhances angiogenesis through a protein kinase G–dependent hypoxia‐inducible factor‐1/vascular endothelial growth factor pathway
  publication-title: Arteriosclerosis, Thrombosis, and Vascular Biology
– volume: 18
  start-page: 39
  year: 2016
  article-title: Role of phosphodiesterase 5 and cyclic GMP in hypertension
  publication-title: Current Hypertension Reports
– volume: 10
  year: 2015
  article-title: The immediate effect of sildenafil on right ventricular function in patients with heart failure measured by cardiac magnetic resonance: A randomized control trial
  publication-title: PLoS ONE
– volume: 35
  start-page: 1863
  year: 2007
  end-page: 1868
  article-title: Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: A double‐blind, placebo‐controlled, randomized, crossover trial
  publication-title: Critical Care Medicine
– volume: 3
  year: 2014
  article-title: Effect of phosphodiesterase inhibition on insulin resistance in obese individuals
  publication-title: Journal of the American Heart Association
– volume: 23
  start-page: 233
  year: 2005
  end-page: 246
  article-title: Endothelial function and dysfunction. Part II: Association with Cardiovascular Risk Factors and Diseases. A Statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension
  publication-title: Journal of Hypertension
– volume: 176
  start-page: S297
  year: 2019
  end-page: S396
  article-title: The concise guide to pharmacology 2019/20: Enzymes
  publication-title: British Journal of Pharmacology
– volume: 353
  start-page: 2148
  year: 2005
  end-page: 2157
  article-title: Sildenafil citrate therapy for pulmonary arterial hypertension
  publication-title: The New England Journal of Medicine
– volume: 9
  start-page: 2122
  year: 2012
  end-page: 2129
  article-title: Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: Implications for clinical safety and improved tolerability
  publication-title: The Journal of Sexual Medicine
– volume: 46
  start-page: D1091
  year: 2018
  end-page: D1106
  article-title: The IUPHAR/BPS guide to pharmacology in 2018: Updates and expansion to encompass the new guide to immunopharmacology
  publication-title: Nucleic Acids Research
– volume: 369
  start-page: 809
  year: 2013
  end-page: 818
  article-title: Macitentan and morbidity and mortality in pulmonary arterial hypertension
  publication-title: The New England Journal of Medicine
– volume: 93
  start-page: 1378
  year: 2004
  end-page: 1383
  article-title: Evaluation of vardenafil and sildenafil on cardiac repolarization
  publication-title: The American Journal of Cardiology
– volume: 53
  year: 2019
  article-title: Haemodynamic definitions and updated clinical classification of pulmonary hypertension
  publication-title: The European Respiratory Journal
– volume: 6
  start-page: 553
  year: 2009
  end-page: 557
  article-title: Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: A phase II clinical trial
  publication-title: The Journal of Sexual Medicine
– year: 2019
  article-title: Phosphodiesterase 5 inhibitors for pulmonary hypertension
  publication-title: Cochrane Database of Systematic Reviews
– volume: 172
  start-page: 1182
  year: 2012
  end-page: 1184
  article-title: Vardenafil for the treatment of Raynaud phenomenon: A randomized, double‐blind, placebo‐controlled crossover study
  publication-title: Archives of Internal Medicine
– volume: 11
  start-page: 67
  year: 2012
  article-title: Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning
  publication-title: Cardiovascular Diabetology
– volume: 53
  start-page: 21S
  year: 2002
  end-page: 30S
  article-title: The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil
  publication-title: British Journal of Clinical Pharmacology
– volume: 6
  year: 2011
  article-title: Sildenafil reduces insulin‐resistance in human endothelial cells
  publication-title: PLoS ONE
– volume: 44
  start-page: 105
  year: 2008
  end-page: 113
  article-title: Essential role of mitochondrial Ca ‐activated and ATP‐sensitive K channels in sildenafil‐induced late cardioprotection
  publication-title: Journal of Molecular and Cellular Cardiology
– volume: 15
  start-page: 707
  year: 2001
  end-page: 713
  article-title: Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men
  publication-title: Journal of Human Hypertension
– volume: 119
  start-page: 408
  year: 2009
  end-page: 416
  article-title: Ventricular phosphodiesterase‐5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice
  publication-title: Circulation
– volume: 152
  start-page: 855
  year: 2007
  end-page: 869
  article-title: Cyclic GMP and protein kinase‐G in myocardial ischaemia‐reperfusion: Opportunities and obstacles for survival signaling
  publication-title: British Journal of Pharmacology
– volume: 12
  start-page: 35
  year: 2014
  article-title: Sildenafil ameliorates oxidative stress and DNA damage in the stenotic kidneys in mice with renovascular hypertension
  publication-title: Journal of Translational Medicine
– volume: 5
  start-page: 689
  year: 2006
  end-page: 702
  article-title: Sildenafil: From angina to erectile dysfunction to pulmonary hypertension and beyond
  publication-title: Nature Reviews. Drug Discovery
– volume: 117
  start-page: 3010
  year: 2008
  end-page: 3019
  article-title: Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double‐blind, placebo‐controlled, multicenter, efficacy (ARIES) study 1 and 2
  publication-title: Circulation
– volume: 338
  start-page: 1397
  year: 1998
  end-page: 1404
  article-title: Oral sildenafil in the treatment of erectile dysfunction
  publication-title: The New England Journal of Medicine
– volume: 50
  start-page: 670
  year: 2007
  end-page: 676
  article-title: Diabetes abolishes sildenafil‐induced cGMP‐dependent protein kinase‐I expression and cardioprotection
  publication-title: Journal of Cardiovascular Pharmacology
– volume: 104
  start-page: 1244
  year: 2018
  end-page: 1250
  article-title: Phosphodiesterase‐5 inhibitors and the heart: Compound cardioprotection?
  publication-title: Heart
– year: 2016
  article-title: Guanylate cyclase stimulators for pulmonary hypertension
  publication-title: Cochrane Database of Systematic Reviews
– volume: 11
  start-page: 150
  year: 1990
  end-page: 155
  article-title: Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors
  publication-title: Trends in Pharmacological Sciences
– volume: 60
  start-page: 80
  year: 2013
  end-page: 88
  article-title: Phosphodiesterase‐5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia/reperfusion injury in type 2 diabetic mice
  publication-title: Free Radical Biology & Medicine
– volume: 278
  start-page: 18791
  year: 2003
  end-page: 18797
  article-title: High glucose inhibits insulin‐stimulated nitric oxide production without reducing endothelial nitric‐oxide synthase Ser1177 phosphorylation in human aortic endothelial cells
  publication-title: The Journal of Biological Chemistry
– volume: 70
  start-page: 147
  year: 2014
  end-page: 154
  article-title: Tadalafil‐induced improvement in left ventricular diastolic function in resistant hypertension
  publication-title: European Journal of Clinical Pharmacology
– volume: 9
  year: 2016
  article-title: Pulmonary vascular distensibility predicts pulmonary hypertension severity, exercise capacity, and survival in heart failure
  publication-title: Circulation. Heart Failure
– volume: 56
  start-page: 1025
  year: 2007
  end-page: 1033
  article-title: Chronic treatment with sildenafil improves energy balance and insulin action in high fat–fed conscious mice
  publication-title: Diabetes
– volume: 379
  start-page: 43
  year: 2013
  end-page: 49
  article-title: Pharmacological postconditioning by bolus injection of phosphodiesterase‐5 inhibitors vardenafil and sildenafil
  publication-title: Molecular and Cellular Biochemistry
– volume: 342
  start-page: 1802
  year: 2000
  end-page: 1813
  article-title: Erectile dysfunction
  publication-title: The New England Journal of Medicine
– volume: 283
  start-page: H1263
  year: 2002
  end-page: H1269
  article-title: Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K ATP channels in rabbits
  publication-title: American Journal of Physiology. Heart and Circulatory Physiology
– volume: 127
  start-page: 1200
  year: 2013
  end-page: 1208
  article-title: Sildenafil and diastolic dysfunction after acute myocardial infarction in patients with preserved ejection fraction
  publication-title: Circulation
– volume: 43
  start-page: S68
  year: 2004
  end-page: S72
  article-title: Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension
  publication-title: Journal of the American College of Cardiology
– volume: 75
  start-page: 1009
  year: 2016
  end-page: 1015
  article-title: Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: The placebo‐controlled SEDUCE study
  publication-title: Annals of the Rheumatic Diseases
– volume: 107
  start-page: 249
  year: 2012
  article-title: Chronic treatment with long acting phosphodiesterase‐5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in type 2 diabetic hearts
  publication-title: Basic Research in Cardiology
– volume: 58
  start-page: 237
  year: 2011
  end-page: 241
  article-title: Tadalafil alters energy metabolism in C2C12 skeletal muscle cells
  publication-title: Acta Biochimica Polonica
– volume: 35
  start-page: S151
  year: 2017
  end-page: S158
  article-title: Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: A randomised, double‐blind, placebo‐controlled study
  publication-title: Clinical and Experimental Rheumatology
– volume: 56
  start-page: 62
  year: 2010
  end-page: 67
  article-title: Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment‐resistant hypertension
  publication-title: Hypertension
– volume: 176
  start-page: 177
  year: 2019
  end-page: 188
  article-title: Nitric oxide synthase enzymology in the 20 years after the Nobel Prize
  publication-title: British Journal of Pharmacology
– volume: 50
  start-page: 903
  year: 2011
  end-page: 909
  article-title: cGMP/PKG pathway mediates myocardial postconditioning protection in rat hearts by delaying normalization of intracellular acidosis during reperfusion
  publication-title: Journal of Molecular and Cellular Cardiology
– volume: 170
  start-page: 843
  year: 1990
  end-page: 850
  article-title: Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle
  publication-title: Biochemical and Biophysical Research Communications
– volume: 388
  start-page: 2665
  year: 2016
  end-page: 2712
  article-title: A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: The Lancet Commission on hypertension
  publication-title: Lancet
– volume: 72
  start-page: 1696
  year: 2013
  end-page: 1699
  article-title: Phosphodiesterase‐5 inhibitors for the treatment of secondary Raynaud's phenomenon: Systematic review and meta‐analysis of randomised trials
  publication-title: Annals of the Rheumatic Diseases
– volume: 124
  start-page: 164
  year: 2011
  end-page: 174
  article-title: Pulmonary hypertension in heart failure with preserved ejection fraction
  publication-title: Circulation
– volume: 396
  start-page: 1054
  year: 2010
  end-page: 1059
  article-title: Sildenafil promotes adipogenesis through a PKG pathway
  publication-title: Biochemical and Biophysical Research Communications
– volume: 19
  start-page: 1427
  year: 2010
  end-page: 1437
  article-title: Avanafil, a new rapid‐onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction
  publication-title: Expert Opinion on Investigational Drugs
– volume: 36
  start-page: 193
  year: 2016
  end-page: 196
  article-title: The relationship between phosphodiesterase‐5 inhibitors and nonarteritic anterior ischemic optic neuropathy
  publication-title: Journal of Neuro‐Ophthalmology
– volume: 88
  start-page: 410
  year: 1998
  end-page: 416
  article-title: Selective pulmonary vasodilation induced by aerosolized zaprinast
  publication-title: Anesthesiology
– volume: 102
  start-page: 1750
  year: 2016
  end-page: 1756
  article-title: Phosphodiesterase type‐5 inhibitor use in type 2 diabetes is associated with a reduction in all‐cause mortality
  publication-title: Heart
– volume: 174
  start-page: 2563
  year: 2017
  end-page: 2575
  article-title: Novel selective PDE type 1 inhibitors cause vasodilatation and lower blood pressure in rats
  publication-title: British Journal of Pharmacology
– volume: 3
  start-page: e2
  year: 2019
  end-page: e3
  article-title: Mortality in the UK STRIDER trial of sildenafil therapy for the treatment of severe early‐onset fetal growth restriction
  publication-title: Lancet Child Adolesc Health
– volume: 78
  start-page: 189
  year: 2018
  end-page: 190
  article-title: Nifedipine cream versus sildenafil cream for patients with secondary Raynaud phenomenon: A randomized, double‐blind, controlled pilot study
  publication-title: Journal of the American Academy of Dermatology
– volume: 307
  start-page: H888
  year: 2014
  end-page: H894
  article-title: Repeated daily dosing with sildenafil provides sustained protection from endothelial dysfunction caused by ischemia and reperfusion: A human in vivo study
  publication-title: American Journal of Physiology. Heart and Circulatory Physiology
– volume: 84
  start-page: 139
  year: 2009
  end-page: 148
  article-title: Erectile dysfunction and cardiovascular disease: Efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions
  publication-title: Mayo Clinic Proceedings
– volume: 136
  start-page: 403
  year: 2016
  end-page: 415
  article-title: Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels
  publication-title: Journal of Neurochemistry
– ident: e_1_2_12_77_1
  doi: 10.1093/rheumatology/ket417
– ident: e_1_2_12_111_1
  doi: 10.1097/WNO.0000000000000299
– ident: e_1_2_12_93_1
  doi: 10.1046/j.1365-2125.2000.00245.x
– ident: e_1_2_12_3_1
  doi: 10.1161/CIRCULATIONAHA.112.000056
– ident: e_1_2_12_47_1
  doi: 10.1161/CIRCULATIONAHA.110.983866
– ident: e_1_2_12_22_1
  doi: 10.1074/jbc.M404706200
– volume: 35
  start-page: S151
  year: 2017
  ident: e_1_2_12_6_1
  article-title: Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: A randomised, double‐blind, placebo‐controlled study
  publication-title: Clinical and Experimental Rheumatology
– ident: e_1_2_12_34_1
  doi: 10.1016/j.neuropharm.2012.06.052
– ident: e_1_2_12_134_1
  doi: 10.1093/rheumatology/keq291
– ident: e_1_2_12_48_1
  doi: 10.1136/annrheumdis-2014-207001
– ident: e_1_2_12_137_1
  doi: 10.1111/bph.14533
– ident: e_1_2_12_32_1
  doi: 10.1056/NEJMoa050010
– ident: e_1_2_12_68_1
  doi: 10.1161/ATVBAHA.108.169722
– ident: e_1_2_12_120_1
  doi: 10.7326/M18-0517
– ident: e_1_2_12_33_1
  doi: 10.1161/CIRCULATIONAHA.107.742510
– ident: e_1_2_12_108_1
  doi: 10.1016/j.amjhyper.2004.07.004
– ident: e_1_2_12_147_1
  doi: 10.1016/S0002-9149(99)00044-2
– ident: e_1_2_12_37_1
  doi: 10.1038/nrd2030
– ident: e_1_2_12_71_1
  doi: 10.1016/j.freeradbiomed.2013.01.031
– ident: e_1_2_12_104_1
  doi: 10.1111/j.1743-6109.2007.00723.x
– ident: e_1_2_12_129_1
  doi: 10.1007/s00228-013-1611-8
– ident: e_1_2_12_56_1
  doi: 10.1053/j.ajkd.2014.09.023
– ident: e_1_2_12_63_1
  doi: 10.1016/S0002-9149(99)00043-0
– ident: e_1_2_12_35_1
  doi: 10.1111/bph.14532
– ident: e_1_2_12_20_1
– ident: e_1_2_12_8_1
  doi: 10.1002/14651858.CD012621.pub2
– ident: e_1_2_12_73_1
  doi: 10.1007/s00395-012-0249-5
– ident: e_1_2_12_150_1
  doi: 10.1517/13543784.2013.793672
– ident: e_1_2_12_2_1
  doi: 10.1111/bph.14752
– ident: e_1_2_12_43_1
  doi: 10.1056/NEJM199805143382001
– ident: e_1_2_12_102_1
  doi: 10.1016/j.vph.2019.05.003
– ident: e_1_2_12_115_1
  doi: 10.1152/ajprenal.00473.2015
– ident: e_1_2_12_30_1
  doi: 10.1016/j.urology.2017.02.044
– ident: e_1_2_12_99_1
  doi: 10.1111/j.1365-2125.2009.03375.x
– ident: e_1_2_12_54_1
  doi: 10.1161/JAHA.114.001001
– ident: e_1_2_12_59_1
  doi: 10.1111/bph.14540
– ident: e_1_2_12_7_1
  doi: 10.2337/db06-0883
– ident: e_1_2_12_80_1
  doi: 10.1002/ejhf.662
– ident: e_1_2_12_140_1
  doi: 10.2337/db11-0255
– ident: e_1_2_12_145_1
  doi: 10.1016/j.yjmcc.2007.10.006
– ident: e_1_2_12_44_1
  doi: 10.1111/jnc.13454
– ident: e_1_2_12_25_1
  doi: 10.1186/1479-5876-12-35
– ident: e_1_2_12_12_1
  doi: 10.1038/sj.bjp.0706495
– ident: e_1_2_12_116_1
  doi: 10.1093/eurheartj/ehm010
– ident: e_1_2_12_135_1
  doi: 10.2337/dc09-1727
– ident: e_1_2_12_144_1
  doi: 10.1111/j.1743-6109.2012.02822.x
– ident: e_1_2_12_24_1
  doi: 10.1016/j.jstrokecerebrovasdis.2015.11.026
– ident: e_1_2_12_23_1
  doi: 10.1038/s41569-019-0176-3
– ident: e_1_2_12_5_1
  doi: 10.1111/bph.14205
– ident: e_1_2_12_74_1
  doi: 10.2174/138161209789206971
– ident: e_1_2_12_142_1
  doi: 10.1371/journal.pone.0045243
– ident: e_1_2_12_21_1
  doi: 10.1016/j.bbrc.2005.06.183
– ident: e_1_2_12_27_1
  doi: 10.1093/ndt/gfs391
– ident: e_1_2_12_53_1
  doi: 10.1016/j.jsxm.2016.01.016
– ident: e_1_2_12_95_1
  doi: 10.4065/84.2.139
– ident: e_1_2_12_28_1
  doi: 10.1371/journal.pone.0119623
– ident: e_1_2_12_36_1
  doi: 10.1016/j.jacc.2007.10.069
– ident: e_1_2_12_75_1
  doi: 10.1161/01.CIR.101.6.676
– ident: e_1_2_12_87_1
  doi: 10.1038/sj.ijir.3901522
– ident: e_1_2_12_81_1
  doi: 10.1056/NEJM200006153422407
– ident: e_1_2_12_114_1
  doi: 10.1210/jc.2015-3415
– ident: e_1_2_12_45_1
  doi: 10.1002/uog.19186
– ident: e_1_2_12_17_1
  doi: 10.1001/archinte.166.2.231
– ident: e_1_2_12_119_1
  doi: 10.1136/annrheumdis-2012-202836
– ident: e_1_2_12_70_1
  doi: 10.1016/S0002-9149(03)00075-4
– ident: e_1_2_12_72_1
  doi: 10.1124/jpet.110.170191
– ident: e_1_2_12_101_1
  doi: 10.1016/S0140-6736(16)31134-5
– ident: e_1_2_12_42_1
  doi: 10.1056/NEJMoa041031
– ident: e_1_2_12_107_1
  doi: 10.1056/NEJMoa1811744
– ident: e_1_2_12_57_1
  doi: 10.1136/heartjnl-2017-312865
– ident: e_1_2_12_139_1
  doi: 10.1159/000334952
– ident: e_1_2_12_82_1
  doi: 10.1152/ajpheart.00129.2010
– ident: e_1_2_12_98_1
  doi: 10.1161/HYPERTENSIONAHA.109.147686
– ident: e_1_2_12_38_1
  doi: 10.1016/j.jacc.2004.02.031
– ident: e_1_2_12_14_1
  doi: 10.1097/00004872-200502000-00001
– ident: e_1_2_12_65_1
  doi: 10.1111/j.1743-6109.2009.01375.x
– ident: e_1_2_12_113_1
  doi: 10.1007/s00228-013-1571-z
– ident: e_1_2_12_136_1
  doi: 10.1183/13993003.01913-2018
– ident: e_1_2_12_106_1
  doi: 10.1177/0271678X17747177
– ident: e_1_2_12_110_1
  doi: 10.1002/j.1939-4640.2004.tb02833.x
– ident: e_1_2_12_131_1
  doi: 10.1016/j.amjmed.2012.08.015
– ident: e_1_2_12_148_1
  doi: 10.1161/HYPERTENSIONAHA.109.132225
– ident: e_1_2_12_16_1
  doi: 10.1001/archinternmed.2012.2271
– ident: e_1_2_12_51_1
  doi: 10.2165/00003495-200565120-00003
– ident: e_1_2_12_62_1
  doi: 10.1111/bph.12959
– ident: e_1_2_12_4_1
  doi: 10.1136/heartjnl-2015-309223
– ident: e_1_2_12_96_1
  doi: 10.1152/ajpheart.00324.2002
– ident: e_1_2_12_117_1
  doi: 10.1001/jama.2013.2024
– ident: e_1_2_12_149_1
  doi: 10.1016/j.jaad.2017.08.018
– ident: e_1_2_12_112_1
  doi: 10.1056/NEJMoa1213917
– ident: e_1_2_12_10_1
  doi: 10.1016/0165-6147(90)90066-H
– ident: e_1_2_12_15_1
  doi: 10.1038/sj.bjp.0707409
– ident: e_1_2_12_126_1
  doi: 10.1074/jbc.M210618200
– ident: e_1_2_12_60_1
  doi: 10.1016/0006-291X(90)92168-Y
– ident: e_1_2_12_29_1
  doi: 10.1161/01.CIR.0000160359.49478.C2
– ident: e_1_2_12_18_1
  doi: 10.1111/jsm.12726
– ident: e_1_2_12_46_1
  doi: 10.1016/j.diabres.2007.02.006
– ident: e_1_2_12_138_1
  doi: 10.1016/j.urology.2017.02.032
– volume: 3
  start-page: 1
  year: 2013
  ident: e_1_2_12_78_1
  article-title: Kidney disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease
  publication-title: Kidney International. Supplement
– ident: e_1_2_12_49_1
  doi: 10.1152/ajprenal.00212.2013
– ident: e_1_2_12_55_1
  doi: 10.1016/S2213-2600(15)00542-1
– ident: e_1_2_12_133_1
  doi: 10.1016/S2352-4642(19)30020-3
– ident: e_1_2_12_64_1
  doi: 10.1097/FJC.0b013e318157fd5b
– ident: e_1_2_12_105_1
  doi: 10.1097/01.CCM.0000269371.70738.30
– ident: e_1_2_12_39_1
  doi: 10.1161/CIRCULATIONAHA.111.063412
– ident: e_1_2_12_58_1
  doi: 10.1097/00000542-199802000-00020
– ident: e_1_2_12_79_1
  doi: 10.1517/13543784.2010.518955
– ident: e_1_2_12_141_1
  doi: 10.1016/0960-894X(96)00323-X
– ident: e_1_2_12_40_1
  doi: 10.1111/j.1742-1241.2009.02254.x
– ident: e_1_2_12_26_1
  doi: 10.1007/s11010-013-1625-7
– ident: e_1_2_12_152_1
  doi: 10.1164/ajrccm.158.5.9710117
– ident: e_1_2_12_41_1
  doi: 10.1111/j.1743-6109.2008.01079.x
– ident: e_1_2_12_90_1
  doi: 10.1111/bph.14167
– ident: e_1_2_12_13_1
  doi: 10.1161/HYPERTENSIONAHA.113.01774
– ident: e_1_2_12_103_1
  doi: 10.1111/j.1743-6109.2008.00945.x
– ident: e_1_2_12_151_1
  doi: 10.1016/j.bbrc.2010.05.064
– ident: e_1_2_12_118_1
  doi: 10.1161/ATVBAHA.109.199893
– ident: e_1_2_12_67_1
  doi: 10.1161/CIRCRESAHA.117.308903
– ident: e_1_2_12_84_1
  doi: 10.1161/CIRCHEARTFAILURE.115.003011
– ident: e_1_2_12_66_1
  doi: 10.1007/s00125-010-1819-4
– ident: e_1_2_12_132_1
  doi: 10.1161/ATVBAHA.107.147421
– ident: e_1_2_12_92_1
  doi: 10.1046/j.0306-5251.2001.00029.x
– ident: e_1_2_12_143_1
  doi: 10.1161/CIRCULATIONAHA.116.022194
– ident: e_1_2_12_50_1
  doi: 10.1093/nar/gkx1121
– ident: e_1_2_12_127_1
  doi: 10.1203/00006450-199802000-00002
– ident: e_1_2_12_128_1
  doi: 10.1530/EJE-15-1100
– ident: e_1_2_12_91_1
  doi: 10.1016/j.amjcard.2004.02.034
– ident: e_1_2_12_121_1
  doi: 10.1378/chest.10-0969
– ident: e_1_2_12_97_1
  doi: 10.3389/fphys.2016.00015
– ident: e_1_2_12_125_1
  doi: 10.1016/j.yjmcc.2006.10.015
– ident: e_1_2_12_146_1
  doi: 10.1002/14651858.CD011205.pub2
– ident: e_1_2_12_9_1
– ident: e_1_2_12_124_1
  doi: 10.1152/ajpheart.ajpheart.91438.2007
– ident: e_1_2_12_83_1
  doi: 10.1038/sj.jhh.1001244
– ident: e_1_2_12_85_1
  doi: 10.1371/journal.pone.0014542
– ident: e_1_2_12_86_1
  doi: 10.1152/ajpheart.00215.2014
– ident: e_1_2_12_89_1
  doi: 10.1186/1475-2840-11-67
– ident: e_1_2_12_100_1
  doi: 10.1161/01.HYP.0000239816.13007.c9
– ident: e_1_2_12_31_1
  doi: 10.1056/NEJMoa1413687
– ident: e_1_2_12_76_1
  doi: 10.1111/bph.13868
– volume: 8
  start-page: 47
  year: 1996
  ident: e_1_2_12_11_1
  article-title: Sildenafil: An orally active type 5 cyclic GMP‐specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction
  publication-title: International Journal of Impotence Research
– ident: e_1_2_12_109_1
  doi: 10.1161/CIRCULATIONAHA.108.822072
– ident: e_1_2_12_69_1
  doi: 10.1016/S0895-7061(00)01177-8
– ident: e_1_2_12_94_1
  doi: 10.1007/s12272-009-1801-1
– ident: e_1_2_12_19_1
  doi: 10.1016/S0735-1097(98)00656-1
– ident: e_1_2_12_88_1
  doi: 10.1007/s11906-016-0646-5
– ident: e_1_2_12_122_1
  doi: 10.18388/abp.2011_2271
– ident: e_1_2_12_123_1
  doi: 10.1161/ATVBAHA.109.201327
– ident: e_1_2_12_130_1
  doi: 10.1681/ASN.2015050473
– ident: e_1_2_12_61_1
  doi: 10.1016/j.yjmcc.2011.02.013
– ident: e_1_2_12_52_1
  doi: 10.2165/00003495-200868020-00006
SSID ssj0014775
Score 2.5929763
SecondaryResourceType review_article
Snippet PDE type 5 inhibitors (PDE5Is), such as sildenafil, tadalafil and vardenafil, are a class of drugs used to prolong the physiological effects of NO/cGMP...
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 5467
SubjectTerms Angina
Cardiovascular diseases
Cerebral infarction
Cyclic GMP
Diabetes mellitus
Erectile dysfunction
Hypertension
Kidney diseases
Myocardial infarction
Review
Sildenafil
TARGETING THE NITRIC OXIDE (NO)‐cGMP PATHWAY: THERAPEUTIC OPPORTUNITIES IN THE 21ST CENTURY
Title Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbph.14920
https://www.ncbi.nlm.nih.gov/pubmed/31721165
https://www.proquest.com/docview/2465744899
https://www.proquest.com/docview/2314255283
https://pubmed.ncbi.nlm.nih.gov/PMC7707100
Volume 177
WOSCitedRecordID wos000510759200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVWIB
  databaseName: Wiley Online Library
  customDbUrl:
  eissn: 1476-5381
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0014775
  issn: 0007-1188
  databaseCode: WIN
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://onlinelibrary.wiley.com
  providerName: Wiley-Blackwell
– providerCode: PRVWIB
  databaseName: Wiley Online Library Full Collection 2020
  customDbUrl:
  eissn: 1476-5381
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0014775
  issn: 0007-1188
  databaseCode: DRFUL
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://onlinelibrary.wiley.com
  providerName: Wiley-Blackwell
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fa9swED5Ku4e9rOt-uuuKNkbZQw2xLFsSe9rahA5KMKNleRgYSZaIYTilbgr973uSHTehGwz2YmR0xrKks76T7r4D-KQzY4zWNE6VojHjVsZKpS5WwrDcamaoCllLzvl0KmYzWWzBl1UsTMcPMWy4ec0I_2uv4Eq3a0qur-ao5pKivb6TJKnweRsoK4YjBMZ5l77AsyAmQvS0Qt6NZ3h0czF6hDAfO0quA9iwAk12_6vtz-FZDzzJ126m7MGWbV7AUdExV98dk4uHQKz2mByR4oHT-u4l_Bojiuwc6Cuimor4uGKf34isBXCRZWtbsnCkOB0Tv7dLMlI381rXPqUPFonZ8H4l_enQK7icjC9OzuI-MUNsEF-MYi2YQyNcaic93EhllSdGOhxeKahJhRMVNyiheGY4c4Yr4SqttBZCuxEum69hu1k09i0QNG8QUKWaS5sznUhNLTUuVxpxlBtpG8Hn1QiVpmct98kzfpcr6wX7sgx9GcHHQfSqo-r4k9DBapjLXlvbkrI842inShnBh6Ea9cwfnqjGLpYokyb4e_NUOBG86WbF8JY02NF5FgHfmC-DgOfw3qxp6nng8uY88CvhZ4b58veGl9-Ks1DY_3fRd_CU-u2B4H1zANs310v7Hp6Y25u6vT4M6oJXPhOHsHP6Y3J5jnc_v0_vAVXpHto
linkProvider Wiley-Blackwell
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fa9swED5KN9hetu63t27Txih7qCGRHUuCvrRbSsqy4IeM9WFgdLJEDMMpdTPof7-T7LgJ3WCwN4POWJbupO9Op-8APuDIGIPI40RrHqfCqljrxMVamjSzmBquQ9WSqZjN5Pm5ynfgaH0XpuWH6ANu3jLCeu0N3AekN6wcLxZk54qTw34nJaDhCzd8P5v1ZwipEG39Ak-DOJSy4xXyeTz9q9u70S2IeTtTchPBhi3o9OH_dX4PHnTQkx23uvIIdmz9GA7ylrv6-pDNb65iNYfsgOU3rNbXT-DHmHBkm0JfMl2XzN8s9hWO2MYVLrZqbMOWjuWfx8xHd9mIVfWiwsoX9aFHZrbyX1l3PvQUvp2O558mcVeaITaEMAYxytSRG67QKQ84ElVmQ6McTbCS3CTSyVIYktBiZETqjNDSlagRpUQ3oI3zGezWy9q-AEYODkGqBIWyWYpDhdxy4zKNhKTcAG0EH9dTVJiOt9yXz_hZrP0XGssijGUE73vRi5as409C--t5Ljp7bQpOCiTIU1Uqgnd9M1maPz7RtV2uSCYZ0gLnyXAieN6qRf-VJHjS2SgCsaUwvYBn8d5uqatFYPMWIjAs0W8Ghfl7x4uTfBIeXv676Fu4N5l_nRbTs9mXV3Cf-2BByMXZh92ry5V9DXfNr6uquXwTbOc3kqUfmw
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fa9swED5KOsZe1v3s3HWbNkbZQw2JLFsS7GVbEjoWghkt9GFgJFkihuGEuhn0v99JdtyEbjDYm0FnLEt30nfS3XcA73VqjNGaxolSNGbcylipxMVKGJZZzQxVoWrJjM_n4vJS5nvwcZML0_JD9Adu3jLCeu0N3K5Kt2XlerVAO5cUHfZ95ovIDGB__H16MetvERjnbQUDT4Q4EqJjFvKRPP3Lu_vRHZB5N1ZyG8OGTWh68H_dfwQPO_BJPrXa8hj2bP0ETvKWvfrmlJzfJmM1p-SE5Le81jdP4ccEkWQbRF8SVZfE5xb7GkdkK4mLrBvbkKUj-XhC_PkuSUlVLypd-bI--EjMTgQs6W6InsHFdHL-5SzuijPEBjHGMNaCOXTEpXbSQ45EltnISIdTLAU1iXCi5AYlFE8NZ85wJVypldZCaDfErfM5DOplbV8AQRcHQVWiubQZ0yOpqaXGZUojlnJDbSP4sJmiwnTM5b6Axs9i48HgWBZhLCN414uuWrqOPwkdb-a56Cy2KSjLUo6-qpQRvO2b0db8BYqq7XKNMskIlzhPhxPBYasW_VeS4EtnaQR8R2F6Ac_jvdtSV4vA58154FjC3wwK8_eOF5_zs_Bw9O-ib-B-Pp4Ws6_zby_hAfWnBSEY5xgG11dr-wrumV_XVXP1ujOe33Y8IEQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Established+and+emerging+therapeutic+uses+of+PDE+type+5+inhibitors+in+cardiovascular+disease&rft.jtitle=British+journal+of+pharmacology&rft.au=Tzoumas%2C+Nikolaos&rft.au=Farrah%2C+Tariq+E.&rft.au=Dhaun%2C+Neeraj&rft.au=Webb%2C+David+J.&rft.date=2020-12-01&rft.issn=0007-1188&rft.eissn=1476-5381&rft.volume=177&rft.issue=24&rft.spage=5467&rft.epage=5488&rft_id=info:doi/10.1111%2Fbph.14920&rft.externalDBID=10.1111%252Fbph.14920&rft.externalDocID=BPH14920
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1188&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1188&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1188&client=summon